Table 1. The characteristics and quality score of the selected clinical trials.
| Author | Year | Country | Study type | Type of suture | Age (FG/SE) | Sample size | Recurrence (%) | Complications (%) | Operating time (FG/SE) | Follow-up (month) | Jadad score | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FG | SE | FG | SE | FG | SE | Mean | SD | Mean | SD | ||||||||
| Koranyi G [22] | 2004 | Sweden | RCT | Vicryl 7-0 | 44/48 | 20 | 23 | 2(10%) | 4(18%) | 0(0%) | 0(0%) | 9.70 | 2.48 | 18.50 | 6.6 | 6.00 | 3 |
| Uy HS [13] | 2005 | Philippines | RCT | nylon 10-0 | 45/45 | 11 | 11 | 0(0%) | 0(0%) | 1(10%) | 1(10%) | 27.80 | 1.00 | 67.00 | 3.60 | 12.00 | 5 |
| Jiang J [23] | 2008 | China | RCT | nylon 10–0 | 57/57 | 20 | 20 | 1(5%) | 2(10%) | 3(15%) | 1(5%) | 17.90 | 2.60 | 31.80 | 3.3 | 6.00 | 2 |
| Ozdamar Y [28] | 2008 | Turkey | RCT | Vicryl 8-0 | 42.6/42.6 | 12 | 12 | 0(0%) | 0(0%) | 0(0%) | 0(0%) | / | / | / | / | 12.00 | 4 |
| Karalezli A [27] | 2008 | Turkey | RCT | Vicryl 8-0 | 53.4/58.5 | 25 | 25 | 1(4%) | 3(12%) | 7(28%) | 12(48%) | 15.70 | 2.40 | 32.50 | 6.70 | 12.00 | 3 |
| Farid M [5] | 2009 | USA | RCT | Vicryl 8-0 | 47.3/52.2 | 27 | 20 | 1(3.7%) | 4(20%) | / | / | / | / | / | / | 12.00 | 3 |
| Coral-Ghanem R [33] | 2010 | Brazil | RCT | Vicryl 8-0 | 42.6/49.3 | 106 | 58 | 12(11.32%) | 15(26%) | / | / | / | / | / | / | 12.00 | 3 |
| Malik VK [34] | 2010 | India | RCT | Vicryl 8-0 | 60.08/60.36 | 25 | 25 | 1(4%) | 3(12%) | 2(8%) | 7(28%) | 18.24 | 2.20 | 26.60 | 1.93 | 13.60 | 2 |
| Cagatay HH [21] | 2014 | Turkey | RCT | Vicryl 8-0 | 52.08/53.75 | 53 | 53 | 1(1.89%) | 4(8%) | 5(10%) | 7(14%) | / | / | / | / | 6.00 | 3 |
| Vichare N [37] | 2013 | India | RCT | nylon 10–0 | 46.8/49.5 | 30 | 30 | 1(3.33%) | 3(10%) | / | / | 34.43 | 4.94 | 50.93 | 4.96 | 13.00 | 3 |
| Sati A [38] | 2014 | India | RCT | Vicryl 8-0 | 40.1/40.9 | 30 | 30 | 2(6.67%) | 3(10%) | 2(7%) | 0(0%) | 15.50 | 1.20 | 27.63 | 1.63 | 6.00 | 3 |
| Cui B [31] | 2009 | China | RCT | nylon 10-0 | 52/55 | 20 | 20 | 0(0%) | 0(0%) | 0(0%) | 0(0%) | 20.50 | 3.60 | 42.80 | 4.5 | 6.00 | 2 |
| Lei QF [41] | 2015 | China | RCT | nylon 10-0 | 52/50 | 30 | 30 | 1(3.33%) | 3(10%) | / | / | 24.50 | 6.50 | 35.20 | 5.4 | 6.00 | 2 |
| Hu JF [43] | 2012 | China | RCT | Vicryl 8-0 | 55.45/53.42 | 46 | 43 | 2(4.35%) | 6(14%) | / | / | 30.65 | 9.43 | 46.56 | 10.24 | 24.00 | 2 |
| Hu QM [42] | 2014 | China | RCT | nylon 10-0 | 52.14/53.14 | 40 | 36 | / | / | / | / | 18.33 | 0.50 | 39.13 | 1.02 | 9.00 | 2 |
| Liu H [40] | 2013 | China | RCT | nylon 10-0 | / | 30 | 30 | 0(0%) | 0(0%) | 1(4%) | 0(0%) | 20.32 | 17.35 | 28.79 | 19.53 | 6.00 | 2 |
| Koranyi G [14] | 2005 | Sweden | non RCT | Vicryl | 44/48 | 258 | 123 | 14(5.43%) | 17(14%) | 13(6%) | 11(9%) | / | / | / | / | 2.00 | / |
| Miranda-Rollón MD [32] | 2009 | Spanish | non RCT | Vicryl 8-0 | 59.8/59.8 | 8 | 9 | 1(12.5%) | 0(0%) | 1(13%) | 4(45%) | / | / | / | / | 29.00 | / |
| Hall RC [26] | 2009 | New Zealand | non RCT | Vicryl 8-0 | 47.8/49.8 | 24 | 23 | 0(0%) | 2(9%) | 10(42%) | 0(0%) | 12.04 | 3.03 | 26.04 | 5.00 | 23.00 | / |
| Ratnalingam V [29] | 2010 | Malaysia | non RCT | Vicryl 8-0 | 60.7/60.7 | 68 | 69 | 3(4.41%) | 11(16%) | 0(0%) | 0(0%) | 16.93 | 2.85 | 29.84 | 5.65 | 1.00 | / |
| Rubin MR [35] | 2011 | Brazil | non RCT | nylon 10-0 | 45.6/47.8 | 21 | 26 | 1(4.76%) | 2(8%) | 1(5%) | 1(4%) | 19.05 | 6.12 | 48.15 | 7.13 | 6.00 | / |
| Yüksel B [20] | 2010 | Turkey | non RCT | Vicryl 8-0 | 53.6/54.6 | 29 | 29 | 2(6.9%) | 4(14%) | 2(7%) | 0(0%) | 23.42 | 13.34 | 41.45 | 3.2 | 21.50 | / |
| Cha DM [36] | 2012 | Korea | non RCT | nylon 10–0 | 63.0/56.9 | 22 | 30 | 1(4.55%) | 6(20%) | 18(82%) | 16(54%) | 27.71 | 5.22 | 43.30 | 8.18 | 6.00 | / |
| Küçükerdönmez C [39] | 2014 | Turkey | non RCT | Vicryl 8-0 | 57.1/52.1 | 13 | 13 | 0(0%) | 0(0%) | / | / | / | / | / | / | 5.00 | / |
/: not available; FG: fibrin glue group; SE: suture group; SD: standard deviation.